Veracyte (VCYT) sees Significant Insider Selling Continuing
10:21PM ET 8/05/2020 MT NewswiresThere was a notable insider sale of Veracyte shares today, as revealed in a filing with the SEC as -- Evan Jones, Director -- sold 40,000 shares in the...
Quotes Snapshot > VCYT
Veracyte Inc VCYT:NASDAQ
Last Price$33.79NASDAQ Closing Price as of 4:00PM ET 8/14/20
Today's Change-1.03(2.96%)
Bid (Size)$27.05 (2)
Ask (Size)$36.00 (1)
Day Low / High$33.73 - 35.03
Volume361.4 K
Read more news Recent News
Veracyte Says Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
3:39PM ET 8/05/2020 MT NewswiresVeracyte (VCYT) said Wednesday that new data showed its Percepta classifier significantly reduces invasive procedures in lung cancer diagnosis by...
Insider Trends: Veracyte Insider Extends 90-Day Selling Trend
8:01PM ET 8/04/2020 MT NewswiresEvan Jones, Director, on Jul 31, 2020, sold 40,000 shares in Veracyte (VCYT) for $1,416,423. Jones, subsequent to the transactions designated in the SEC...
Veracyte Kicks off Underwritten Offering of 6 Million Shares
2:06PM ET 8/04/2020 MT NewswiresVeracyte (VCYT) said late Monday it has begun an offering of 6 million shares. It also plans to offer underwriters a 30-day option to purchase up to...
View all Commentary and Analysis
Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q2 2020 Results - Earnings Call Transcript
11:36PM ET 8/02/2020 Seeking AlphaVeracyte (VCYT) Presents At UBS Global Healthcare Conference - Slideshow
3:57PM ET 5/20/2020 Seeking AlphaVeracyte, Inc. (VCYT) CEO Bonnie Anderson on Q1 2020 Results - Earnings Call Transcript
10:54AM ET 5/09/2020 Seeking AlphaVeracyte, Inc. 2020 Q1 - Results - Earnings Call Presentation
1:41PM ET 5/08/2020 Seeking AlphaCompany Profile
Business DescriptionVeracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 6000 Shoreline Court South San Francisco, California 94080 |
| Phone | +1.650.243.6300 |
| Number of Employees | 270 |
| Recent SEC Filing | 08/12/2020 4 |
| Chairman & Chief Executive Officer | Bonnie H. Anderson |
| Chief Operating & Financial Officer | Keith Kennedy |
| Chief Scientific & Medical Officer | Giulia C. Kennedy |
| Secretary, Executive VP & General Counsel | James H. Erlinger |
Company Highlights
| Price Open | $34.92 |
| Previous Close | $34.82 |
| 52 Week Range | $13.90 - 36.42 |
| Market Capitalization | $1.7 B |
| Shares Outstanding | 50.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 10/27/2020 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.62 |
| Beta vs. S&P 500 | N/A |
| Revenue | $92.0 M |
| Net Profit Margin | -27.49% |
| Return on Equity | -13.35% |
Analyst Ratings as of 05/28/2020
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |